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We thank Dr. Aulakh for his comments1 which we will address point by point.  
It’s unlikely that the relationship between neurocysticercosis (NCC) and 
seizures/epilepsy will change according to different definitions.2 The prognosis of 
parenchymal NCC is generally good although seizure recurrence occurs in about 
one-third of people with parenchymal NCC,3,4 most do not develop late epilepsy. 
Seizures associated to genetic syndromes such as absence, are not relevant to 
NCC, as there is no causal relationship with NCC. The co-existence of absence 
seizures and NCC is likely to be coincidental in endemic areas.   
We partly agree with Dr. Aulakh regarding the use of immunological tests. Costs, 
technical issues and logistics make their use challenging in many endemic areas 
particularly enzyme-linked immunoelectrotransfer blot (EITB). This is less of an 
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issue with enzyme-linked immunosorbent assay (ELISA), included in our diagnostic 
criteria. In-house ELISAs are economical and simple to do and although their 
sensitivity and specificity in sera are not optimal, they provide valuable 
complementary information to the epidemiological, clinical, and radiological 
diagnostic data. CSF immunological tests are of much value in the case of 
extraparenchymal NCC as specificity of 90-100% has been reported substantially 
decreasing the risk of false positives.5  
Dr. Aulakh expressed concerns about the use of X-rays of limbs as a criterion for 
the diagnosis of probable parenchymal NCC. We do share the concerns, however, 
the exposure to radiation generated by limbs X-rays particularly as one off, is very 
low and there is no direct epidemiological data to support increased cancer risk in 
such scenarios.6 
We agree that the differential diagnosis between NCC and tuberculoma is a point 
of concern. For this reason, an individual with epilepsy from an endemic area with 
a cerebral cyst will only have a probable (and not definitive) diagnosis of 
parenchymal NCC and as we stated there will be a need to “establish differential 
diagnoses with other etiologies,”.   
Lastly, as Dr. Aulakh stated, it will be almost impossible to have a perfect 
diagnostic criteria for NCC in view of the great heterogeneity of the condition. We 
are conscious that our criteria can be improved, perhaps as a result of an 
international effort. Our criteria were established by a Latin American team and it is 
possible that some aspects may be improved in Asia and Africa. Taking into 
account the area of origin of a suspected case to define different criteria is an 
interesting idea to consider. Migration from country to country is, however, frequent 
and disparities in socioeconomic status exist within countries, so it may be difficult 
to implement. Developing internationally accepted diagnostic criteria for NCC 
should be considered. Meetings with specialists from around the world is essential 
to identify NCC particularities in specific area and to determine how to improve and 
validate it criteria for them.  
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